![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » Roche Pitches in on Regeneron’s COVID-19 Antibody Combination
Roche Pitches in on Regeneron’s COVID-19 Antibody Combination
![roche.gif](https://www.fdanews.com/ext/resources/test/Device_Images/roche.gif?t=1600727553&width=430)
Swiss pharma giant Roche announced that it is partnering with Regeneron Pharmaceuticals to ramp up production of the New York-based biotech’s COVID-19 antibody cocktail candidate, REGN-COV2.
Under the deal, the two companies will dedicate annual manufacturing capacity for the double-antibody combination, and they expect to increase capacity “to at least three-and-a-half times the current capacity, with the potential for even further expansion,” Roche said.
As part of the agreement, Roche will handle worldwide distribution outside the U.S. if the two-antibody combination gets regulatory approval.
Upcoming Events
-
21Oct